OVERVIEW

Dual Antiplatelet Therapy in Coronary Artery Disease: New Guidelines and Beyond is organized by Rockpointe Corporation.

Release date: November 12, 2019
Expiration date: November 12, 2020

Accreditation:
Physician Credit Designation?
The University of North Texas Health Science Center designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Overview:
It is estimated that 720,000 Americans will have a new coronary event and 335,000 will have a recurrent event this year. Guidelines recommend that these patients receive dual antiplatelet therapy (DAPT) with low-dose ASA and a platelet P2Y12 receptor antagonist (clopidogrel, prasugrel, or ticagrelor). While there is agreement that low-dose ASA therapy should be continued indefinitely, research continues to lead to modifications of the recommendations for P2Y12 receptor antagonists. To address this, in 2016 the ACC and AHA jointly published a focused guideline update on the use of DAPT in CAD. However, many clinicians are not yet following these recommendations, either because they are not familiar with them or because they are skeptical about the applicability of randomized clinical trials to their practices.

Educational Objectives:
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of this activity, participants should be able to:
• Apply the 2016 ACC/AHA guideline focused update on DAPT recommendations when developing individualized management plans for patients with CAD
• Consider the results of recent clinical trials investigating the optimal management of DAPT when creating management plans for patients with CAD
• Identify validated tools that can be used to individualize DAPT therapy

Additional details will be posted as soon as information is available.